Patent · US Active

Avermectins and milbemycins for the treatment, prevention or amelioration of flavivirus infections

US8741856B2 · kind B2 · utility

1Cited by

1References

7Claims

0Family size

Assignees

CONSIGLIO NAZIONALE DELLE RICERCHE · IT
Aix-Marseille Universite · FR
Katholieke Universiteit Leuven, KU LEUVEN R&D · BE

Inventors

Mario Milani de Mayo de Mari · Milano, IT
Eloise Mastrangelo · Milano, IT
Martino Bolognesi · Pavia, IT
Xavier De Lamballerie · Châteauneuf-les-Martigues, FR
Boris Pastorino · Marseilles, FR
Johan Neyts · Namur, BE
Suzanne Kaptein · Leuven, BE

Key dates

Filing date	Oct 21, 2010
Grant date	Jun 3, 2014
Priority date	—
Expiry date	Dec 1, 2030

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Avermectin and milbemycin compounds, particularly the substance ivermectin, for preparing an antiviral medicament for the treatment, prevention or amelioration of a Flavivirus infection, such as those caused by YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) or MODV (Modoc virus) are provided. The antiviral compositions of the present invention are suitable for oral administration to a Flavivirus-infected subject or a subject at risk of a infection, such as a human or other mammal.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.